Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model

By sjmartinez • October 16, 2023

Iannone V, Babu AF, Lok J, Gómez-Gallego C, D'Auria G, Vazquez-Uribe R, Vaaben TH, Bongers M, Mikkonen S, Vaittinen M, Tikkanen I, Kettunen M, Klåvus A, Sehgal R, Kaminska D, Pihlajamaki J, Hanhineva K, El-Nezami H, Alexander Sommer MO, Kolehmainen M. Changes in liver metabolic pathways demonstrate efficacy of the combined dietary and microbial therapeutic intervention in MASLD mouse model. Mol Metab. 2023 Oct 13:101823. doi: 10.1016/j.molmet.2023.101823. Epub ahead of print. PMID: 37839774.

Tags: aldafermin, Cardiology/Epi, genetically modified E. coli Nissle 1917, Metabolic dysfunction-associated steatotic liver disease, non-alcoholic fatty liver disease, non-targeted metabolomics, omics integration, Publications, Transcriptomics

Related Posts

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin[...]

Blood Pressure Genetic Risk and Incident Hypertension at 2 to 7 Years Post Partum

Hemeryck J, De Moor N, Ezzat D, Khan RR, Vandergrift N, Levine LD, Rouse C, Theilen LH, Bairey Merz CN, Yee LM, Chung J, Bello[...]

Time to Quadruple Therapy After Initial Diagnosis of Heart Failure With Reduced Ejection Fraction

Jacobs JA, Greene T, Vanneman ME, Kean J, Carter SJ, Shah KS, Pandey A, Derington CG, Zheutlin AR, Fang J, Stehlik J, Fonarow GC, Bress[...]